Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of Abeona Therapeutics stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $5.10, for a total value of $20,400.00. Following the completion of the sale, the director now directly owns 68,334 shares in the company, valued at approximately $348,503.40. This represents a 5.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Abeona Therapeutics Stock Performance

ABEO stock traded down $0.03 during midday trading on Tuesday, reaching $5.19. 406,367 shares of the company were exchanged, compared to its average volume of 314,281. The firm has a market capitalization of $225.61 million, a price-to-earnings ratio of -1.93 and a beta of 1.46. The business has a 50-day moving average price of $5.83 and a two-hundred day moving average price of $5.72. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its stake in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares in the last quarter. abrdn plc boosted its holdings in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the period. Western Standard LLC grew its position in shares of Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after purchasing an additional 110,998 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after purchasing an additional 83,050 shares during the period. Finally, Rosalind Advisors Inc. raised its position in shares of Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after buying an additional 82,000 shares in the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.